This new Kids First data creates a fuller understanding of how genetics contributes to childhood cancers and congenital disorders, opening additional doors for prevention and treatment. 

In a study recently published by researchers at Fox Chase Cancer Center, patients being treated for retroperitoneal sarcoma at multiple facilities experienced longer delays between diagnosis and treatment and traveled farther to receive treatment, but their overall survival rates were equivalent to patients receiving nonfragmented care.

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to Cambridge researchers. In a trial where cancers were treated with chemotherapy followed by a targeted cancer drug before surgery, 100% of patients survived the critical three-year period post-surgery.

IRB Barcelona researchers have developed a new computational tool that tracks the evolutionary shifts in selection pressure during tumorigenesis and chemotherapy.

Using more than 8,500 cancer whole-genome sequences, the team identified 11 cancer driver genes linked to chemoresistance to specific anticancer drugs.

The study has been published in the journal Nature Communications.